Wai Conrad sold $1.4M of CLOV (indirect holdings)

Wai Conrad (CEO, Counterpart Health) sold 300,000 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.72 ($1.42M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wai Conrad
Published Sep 16, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Bearish
medium confidence
Mentioned
$CLOV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVBearishLow
01

Why it matters

The disclosed sale reduces the CEO's ownership but follows a pre‑arranged plan, limiting immediate market impact.

02

Market read

Primary relevance is to CLOV shareholders; broader market effect is limited.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 5/10Novelty 4/10Timing: filed after market close on 2026-09-16

Background

Clover Health Investments filed a Form 4 reporting an insider transaction by its CEO.

Company-level read

Ticker impact

$CLOVBearishMedium confidence
Context

CEO Wai Conrad sold 300,000 shares for $1.416M via a 10b5-1 plan, reducing his stake to 1,170,056 shares.

Expected impact

possible modest downside of 1-2% in the near term

Evidence & confidence

Large insider sale of $1.4M, but executed under a pre‑arranged plan, limits immediate market reaction.

Market effects

Minimal impact on health‑tech sector; similar insider sales have limited sector ripple.

U.S. market only; no broader regional effect.

Low global relevance.

Counterpoint

The sale could be routine liquidity management, not a bearish signal.

Key entities

  • Wai Conrad

    CEO of Clover Health Investments, Counterpart Health

  • Clover Health Investments, Corp.

    U.S.-listed health‑tech firm (ticker CLOV)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.